Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781450 | 1.00 | MCL1 (0.45) | MCL1ABCB1KLK7FKBP1ANR1H2 | |
| SCHEMBL1781452 | 1.00 | MCL1 (0.45) | MCL1ABCB1KLK7FKBP1ANR1H2 | |
| SCHEMBL7149261 | 0.92 | POLB (0.43) | MCL1ABCB1KLK7POLB | |
| SCHEMBL21066263 | 0.91 | KLK7 (0.47) | MCL1ABCB1KLK7FKBP1ANR1H2 | |
| SCHEMBL22322657 | 0.90 | KLK7 (0.48) | KLK7FKBP1ANR1H2NR1H3 | |
| SCHEMBL29550939 | 0.90 | KLK7 (0.48) | KLK7FKBP1ANR1H2NR1H3 | |
| SCHEMBL1448111 | 0.87 | ABCB1 (0.54) | MCL1ABCB1KLK7FKBP1AUCHL1 | |
| SCHEMBL21273903 | 0.87 | ABCB1 (0.54) | MCL1ABCB1KLK7FKBP1AUCHL1 | |
| SCHEMBL7703700 | 0.87 | ABCB1 (0.54) | MCL1ABCB1KLK7FKBP1AUCHL1 | |
| SCHEMBL7279798 | 0.87 | ABCB1 (0.54) | MCL1ABCB1KLK7FKBP1AUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678238-A2 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-3752251-B1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2025-01-14 | — | — | US | disclosed |
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2024-02-27 | — | — | US | disclosed |
| CN-117180290-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| CN-111712302-B | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230122859-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11420984-B2 | Arginase inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2022-08-23 | — | — | US | disclosed |
| US-20080119464-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912727-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MCL1 1172/4885ABCB1 870/4885KLK7 4255/4885 |
| US-12195485-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, PRMT1 | MCL1 905/4885ABCB1 815/4885KLK7 4347/4885 |
| US-20230122859-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, PRMT1 | MCL1 905/4885ABCB1 815/4885KLK7 4347/4885 |
| US-20080119464-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | MCL1 3879/4885ABCB1 329/4885KLK7 1127/4885 |
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MCL1 1172/4885ABCB1 870/4885KLK7 4255/4885 |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MCL1 1172/4885ABCB1 870/4885KLK7 4255/4885 |
| US-11420984-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MCL1 1110/4885ABCB1 863/4885KLK7 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.